Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer


Press Release Prof. Nutt Will Drive Progression of a Pipeline of New Psychedelic Medicines, Helping to Define a Clear Development Pathway to Treat Addiction Through Psychedelic Medicines Toronto, Ontario–(Newsfile Corp. – June 24, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat Addiction, announced today that globally renowned neuroscientist and addiction researcher, Prof. David Nutt, has joined its executive team as Chief Research Officer. This appointment is driven by the expansion of Awakn’s psychedelic drug and therapy development pipeline targeting Addiction. In particular the identification, and development of several potential new candidates with unique properties to better treat a broad range of addictions, acquired from Prof. David Nutt’s Equasy Enterprises in March 2021; the licencing of the intellectual property from world’s only Ketamine-Assisted Psychotherapy trial for Alcohol Use Disorder (AUD) from the University of Exeter in March 2021. And finally, the world’s only Phase IIb trial for MDMA-Assisted Psychotherapy for AUD. In this new role, which is in addition to Prof. Nutt’s existing role as Chair of Awakn’s Scientific Advisory Board, Prof. Nutt will lead Awakn’s neuroscience research of psychedelic compounds for treating a broad range of addictions where the consequences for the patient, their family, and society are at present most severe. Prof. Nutt will work closely with Dr. Shaun McNulty, Awakn’s Chief Scientific Officer, who leads Awakn’s Pre-Clinical stage and Clinical stage research and development programs. Professor David Nutt commented, “I am delighted to take on the role of Chief Research Officer in this exciting new biotechnology company that promises to revolutionise the treatment of addictions. Awakn’s combination of pre-clinical and clinical research uniquely positions Awakn to solve some of the biggest societal problems.” Anthony Tennyson, Awakn’s CEO commented, “Our ambition is to fully integrate…

Excerpt only …
Source : Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.